SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- Metabasis Therapeutics, Inc. announced today that it will present at the BIO CEO & Investor Conference on February 14, 2006 at 12:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York, NY. Dr. Paul Laikind, chairman, CEO and president of Metabasis is expected to provide a business overview and discuss the Company’s product pipeline, accomplishments in 2005 and goals for 2006.
To access the live broadcast and the subsequent archived recording of the presentation, please log onto the Company’s website at www.mbasis.com under the “Investors” section. The audio recording and presentation will be archived there for 30 days following the live presentation. Please connect to Metabasis’ website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics, Inc. is a biopharmaceutical company uniquely focused on the discovery, development and eventual commercialization of novel drugs to address some of the world’s most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting large markets with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(TM) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics, Inc.
CONTACT: Paul Laikind, Ph.D., Chairman, CEO & President of MetabasisTherapeutics, Inc., +1-858-622-5550
Web site: http://www.mbasis.com/
